Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice1

By E. Cretney, K. Takeda, H. Yagita, M. Glaccum, J. Peschon, M. Smyth. Journal of Immunology, 2002

671 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. (2015, background): “%) had increased expression of TRAIL (Figure S2) raising the possibility that this LDN subpopulation may play a role in antitumor immunity (Cretney et al., 2002).”
How Do Cytotoxic Lymphocytes Kill Cancer Cells? (2015, background): “This effect was originally shown using transplanted syngeneic cell lines (11, 54, 60, 61) and later confirmed in a more physiologic model of spontaneous metastasis during chemically induced carcinomas (62).”
Apo2L/TRAIL and its death and decoy receptors (2003, result): “Cretney et al.71 confirmed many of these results in Apo2L/ TRAIL-deficient mice.”
TRAIL and apoptosis induction by TNF-family death receptors (2003, background): “Mouse gene knockout studies indicate that TRAIL has an important role in antitumor surveillance by immune cells (Cretney et al., 2002; Smyth et al., 2003), and mediates thymocyte apoptosis and is important in the induction of autoimmune diseases (Lamhamedi-Cherradi et al., 2003).”
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. (2003, background): “Apo2L/TRAIL knockout mice are viable, fertile and have no obvious haematological defects [104,105], suggesting this death ligand does not have an essential developmental function.”